 Eli Lilly Co. Inc. and Sosei Group Corp. said Friday they plan to develop and commercialize therapies for diabetes and metabolic diseases. Lilly is paying the Japanese drug maker an upfront payment of 37 million, with potential milestone payments up to 694 million in addition to tiered royalties on sales. 